• Payments for R&D trended up as the company began enrolment in post-approval study
• Advertising and marketing costs increased to support commercialization
• Administration and corporate costs trended higher due to prepayment of D&O insurance

EBR Systems, Inc. (ASX: EBR), the developer of the world's only wireless cardiac pacing device for heart failure, has released its Quarterly Cash Flow Report for the quarter ended 31 December 2025. This report supplements the company's Form 10-K (audited annual financial report) filed with the U.S. Securities and Exchange Commission. The key highlights from the report include:- Payments for research and development trended up as the company began enrolment in the post-approval study, and increased development spending.- Advertising and marketing costs increased to support the company's commercialization efforts.- Administration and corporate costs trended higher, primarily due to the prepayment of the company's annual D&O insurance premiums.The report provides detailed cash flow information across operating, investing, and financing activities for the quarter and full year ended 31 December 2025. It also includes comparative data for the previous three quarters.EBR Systems is dedicated to superior treatment of cardiac rhythm disease by providing more physiologically effective stimulation through its patented Wireless Stimulation Endocardially (WiSE) technology. The company's initial product is designed to eliminate the need for coronary sinus leads to stimulate the left ventricle in heart failure patients requiring Cardiac Resynchronisation Therapy (CRT).